Europe
Secarna Pharmaceuticals to attend BIO-Europe® 2018 - 24th Annual International Partnering Conference
Secarna Pharmaceuticals today announced that the Company will participate in the upcoming BIO-Europe®2018 – 24th Annual International Partnering Conference taking place from November 5 to 7, 2018 in Copenhagen, Denmark.
Primary Endpoint was met, with rhC1INH treatment reducing neutrophil gelatinase-associated lipocalin (NGAL), a widely recognized marker of acute renal damage
Bioavailability significantly higher than with oral administration
Brand, name, CI and website for Joyn Bio created by Cc – Circle Culture Consulting. The core task consisted of finding the appropriate visual language to communicate the innovations of the new synthetic biology company.
Endomag has won a prestigious British Business Innovation Award from the Institute of Physics (IOP), presented at the Houses of Parliament in London.
Five oral and poster presentations highlight utility of OncoDNA’s comprehensive testing of cancer biomarkers and cancer treatment database
Amryt’s lead commercial product now available in all five of the EU’s largest markets
MDxHealth SA (Euronext Brussels: MDXH) (“MDxHealth” or the “Company”), announced that it received on October 12, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the “Belgian Transparency Act”).
Amphion Innovations plc announces that the Company has agreed terms for re-structuring the loan payments under the Facility and the draw-down of an additional US $1.1 million (net after fees and expenses) under the loan facility as announced on 5 June 2014 (the “Facility”).
Higher dose met primary endpoint, the Overall Neuropathy Limitation Scale (ONLS), with statistical significance (p = 0.008)
PRESS RELEASES